Perseus Proteomics, Inc. (JP:4882) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Perseus Proteomics Inc. has announced the extension of its phase I/II clinical trial for its drug PPMX-T003, targeting the rare aggressive NK-cell leukemia, until March 2026 due to challenges in subject registration. The company is analyzing the potential impact of this extension on its financial results for the current and following fiscal years.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.